MA39956A - Analogues du benzomorphane et leur utilisation - Google Patents

Analogues du benzomorphane et leur utilisation

Info

Publication number
MA39956A
MA39956A MA039956A MA39956A MA39956A MA 39956 A MA39956 A MA 39956A MA 039956 A MA039956 A MA 039956A MA 39956 A MA39956 A MA 39956A MA 39956 A MA39956 A MA 39956A
Authority
MA
Morocco
Prior art keywords
benzomorphan
analogs
benzomorphan analogs
diastereomers
solvates
Prior art date
Application number
MA039956A
Other languages
English (en)
Inventor
R Richard Goehring
Laykea Tafesse
Jiangchao Yao
Jianming Yu
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MA39956A publication Critical patent/MA39956A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés tels que représentés par la formule i ou i' et des sels, solvates, et diastéréoisomères pharmaceutiquement acceptables de ceux-ci : dans laquelle r1, r2, r2a, r3, et r4 sont tels que définis dans la description. L'invention concerne également des composés de formules ii, iii, a a-h et des sels, solvates et diastéréoisomères pharmaceutiquement acceptables de ceux-ci. Dans certains modes de réalisation, les composés de l'invention sont utiles pour le traitement de la douleur, de la constipation, et d'autres pathologies comme le souligne la description. Sans souhaiter être lié par une quelconque théorie, on pense que les composés de l'invention sont efficaces dans le traitement de pathologies qui sont modulées par l'activité de récepteurs opioïdes et/ou orl-1.
MA039956A 2014-05-06 2015-05-05 Analogues du benzomorphane et leur utilisation MA39956A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461989129P 2014-05-06 2014-05-06

Publications (1)

Publication Number Publication Date
MA39956A true MA39956A (fr) 2015-11-12

Family

ID=54392885

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039956A MA39956A (fr) 2014-05-06 2015-05-05 Analogues du benzomorphane et leur utilisation

Country Status (6)

Country Link
US (1) US9975854B2 (fr)
EP (1) EP3139921A4 (fr)
JP (1) JP6386088B2 (fr)
CA (1) CA2948144A1 (fr)
MA (1) MA39956A (fr)
WO (1) WO2015171553A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150210646A1 (en) * 2012-05-11 2015-07-30 Purdue Pharma L.P. Benzomorphan compounds as opioid receptors modulators
EP3333156A3 (fr) * 2012-11-09 2018-09-26 Purdue Pharma L.P. Analogues de benzomorphane et leur utilisation
EP3087078B1 (fr) 2013-12-26 2019-05-15 Purdue Pharma LP Analogues 7-bêta-alkyle d'orvinols
EP3087079B1 (fr) 2013-12-26 2019-04-03 Purdue Pharma LP Morphinanes oxabicyclo[2.2.2]octane modulateurs des récepteurs aux opiacés
EP3087073B1 (fr) 2013-12-26 2018-07-04 Purdue Pharma LP Hydantoïnes de morphinane substitués en position 10
AU2014370062A1 (en) 2013-12-26 2016-08-11 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
US9902726B2 (en) 2013-12-30 2018-02-27 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
EP3154972A4 (fr) 2014-06-13 2017-11-22 Purdue Pharma L.P. Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
KR20190098253A (ko) * 2017-01-05 2019-08-21 타이완제이 파마슈티컬스 컴퍼니 리미티드 모르피난 유도체, 및 자가면역, 염증 또는 감염 관련 질환을 치료하기 위한 이를 포함하는 조성물
CN114591247A (zh) * 2020-12-04 2022-06-07 鲁南制药集团股份有限公司 一种替莫唑胺中间体化合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138603A (en) * 1958-10-31 1964-06-23 Everette L May New benzomorphans (methanobenzazocines) and preparation thereof
US4009171A (en) * 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
GB1511319A (en) * 1974-09-20 1978-05-17 Sterling Drug Inc 2,6-methane-3-benzazocine derivatives and their preparation
US4108857A (en) * 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
GB1575009A (en) * 1976-06-21 1980-09-17 Acf Chemiefarma Nv 6,7-benzomorphan derivatives
US4150032A (en) * 1978-01-18 1979-04-17 Bristol-Myers Company 9-Oxobenzomorphan process and intermediates
NL7907800A (nl) 1979-10-23 1981-04-27 Acf Chemiefarma Nv Nieuwe 6,7-benzomorfanderivaten en zuuradditiezouten daarvan, farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werkwijze voor het bereiden van deze verbindingen en de farmaceutische preparaten.
DE2943805A1 (de) 1979-10-30 1981-05-27 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 3-phenoxy-benzaldehyden
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
NZ500590A (en) 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AU732329B2 (en) 1997-05-30 2001-04-12 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative
DE69842004D1 (de) 1997-11-21 2010-12-30 Purdue Neuroscience Co Substituierte 2-aminoacetamide und anwendung davon
TR200003598T2 (tr) 1998-03-26 2001-06-21 Japan Tobacco Inc. Amid türevleri ve nosiseptin antagonistleri
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
UA72244C2 (en) 1999-03-26 2005-02-15 Aryl-substituted pyrazols, imidazols, oxazols, thiazols, pyrrols and their use
CA2370030C (fr) 1999-04-09 2007-08-14 Euro-Celtique S.A. Composition de blocage du canal sodique et leur utilisation
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
WO2001072714A2 (fr) 2000-03-24 2001-10-04 Euro-Celtique S.A. Pyrazoles, triazoles et tetrazoles a substitution aryle et leur utilisation
AU2001249610B2 (en) 2000-03-31 2005-03-24 Euro-Celtique S.A. Aminopyridines and their use as anticonvulsants and sodium channel blockers
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
MXPA04000411A (es) 2001-07-16 2004-03-18 Euro Celtique Sa Tiazolidinonas arilo sustituidas y uso de las mismas.
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
KR20050026031A (ko) 2002-07-31 2005-03-14 유로-셀티큐 에스.에이. 아릴 치환된 벤즈이미다졸 및 나트륨 채널 차단제로서이의 용도
JP2005538101A (ja) 2002-07-31 2005-12-15 ユーロ−セルティーク エス．エイ． アリール置換ヒダントイン化合物及びナトリウムチャネルブロッカーとしてのその使用
US20040152696A1 (en) 2002-08-01 2004-08-05 Euro-Celtique S.A. 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
WO2005014849A2 (fr) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associes a des reponses a des douleurs neuropathiques
GB0619333D0 (en) * 2006-09-30 2006-11-08 Univ Liverpool Dispiro tetraoxane compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP3090739A1 (fr) * 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions constituées de sodium de naproxène et nizatidine
EP2582666B1 (fr) 2010-06-16 2014-08-13 Purdue Pharma L.P. Indoles à substitution aryle et leur utilisation en tant que bloqueur des canaux sodium
WO2012007836A1 (fr) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Composés pyridines comme bloqueurs des canaux sodiques
EP2616441B1 (fr) 2010-09-17 2019-08-07 Purdue Pharma L.P. Composés de pyridine et ses utilisations
JP2013540130A (ja) 2010-10-05 2013-10-31 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのキナゾリン化合物
CA2822789A1 (fr) 2010-12-22 2012-06-28 Purdue Pharma L.P. Pyridines substituees en tant que bloqueurs de canaux sodiques
WO2013002511A2 (fr) 2011-06-30 2013-01-03 서울반도체 주식회사 Lampe à del
WO2013021276A1 (fr) 2011-08-10 2013-02-14 Purdue Pharma L.P. Antagonistes du trpv1 comprenant un substituant dihydroxy et leurs utilisations
TW201331186A (zh) 2011-09-02 2013-08-01 Purdue Pharma Lp 作為鈉通道阻斷劑之嘧啶類
WO2013064884A1 (fr) 2011-10-31 2013-05-10 Purdue Pharma L.P. Amines quaternisées en tant que bloqueurs des canaux sodiques
WO2013064883A1 (fr) 2011-10-31 2013-05-10 Purdue Pharma L.P. Composés hétéroaryliques comme agents de blocage des canaux sodiques
WO2013072758A1 (fr) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides comme bloqueurs des canaux sodiques
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
US20150210646A1 (en) * 2012-05-11 2015-07-30 Purdue Pharma L.P. Benzomorphan compounds as opioid receptors modulators
EP3333156A3 (fr) 2012-11-09 2018-09-26 Purdue Pharma L.P. Analogues de benzomorphane et leur utilisation
TWI513697B (zh) 2012-12-14 2015-12-21 Purdue Pharma Lp 吡啶酮並嗎啡喃類似物及其對類鴉片受體之生物活性
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9056836B2 (en) * 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
EP3293184B1 (fr) 2013-03-04 2020-12-16 Purdue Pharma L.P. Pyrimidine carboxamides à titre de bloqueurs des canaux sodiques
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
CA3082427A1 (fr) 2013-03-15 2014-09-25 Purdue Pharma L.P. Derives de carboxamide et leur utilisation
AU2014270109B2 (en) 2013-05-24 2017-05-25 Rhodes Technologies Opioid ketal compounds and uses thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3087073B1 (fr) 2013-12-26 2018-07-04 Purdue Pharma LP Hydantoïnes de morphinane substitués en position 10
US9902726B2 (en) 2013-12-30 2018-02-27 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof

Also Published As

Publication number Publication date
WO2015171553A1 (fr) 2015-11-12
EP3139921A4 (fr) 2018-02-14
US9975854B2 (en) 2018-05-22
CA2948144A1 (fr) 2015-11-12
JP2017514863A (ja) 2017-06-08
EP3139921A1 (fr) 2017-03-15
JP6386088B2 (ja) 2018-09-05
US20170073313A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
MA39956A (fr) Analogues du benzomorphane et leur utilisation
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MA39749A (fr) Dérivés de pipéridine-dione
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
WO2016011390A8 (fr) Agents d'inhibition de l'irak 4
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12017501523A1 (en) Selective bace1 inhibitors
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12018500282A1 (en) Cgrp receptor antagonists
PH12016501483B1 (en) P-substituted asymmetric ureas and medical uses thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
GEP20186893B (en) Pyrazines modulators of gpr6
PH12018500668A1 (en) Therapeutic compounds and methods of use thereof
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
IN2013MU02010A (fr)
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.